BTX
Overvalued by 93.6% based on the discounted cash flow analysis.
Market cap | $808.80 Million |
---|---|
Enterprise Value | $808.80 Million |
Dividend Yield | $0.97 (10.74%) |
Earnings per Share | $0.17 |
Beta | 1.32 |
Outstanding Shares | - |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 41.9 |
---|---|
PEG | 11.15 |
Price to Sales | - |
Price to Book Ratio | - |
Enterprise Value to Revenue | 1352.51 |
Enterprise Value to EBIT | -43.15 |
Enterprise Value to Net Income | -19 |
Total Debt to Enterprise | 0 |
Debt to Equity | 0 |
No data
No data
Brooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to a...